Medicare Spending on New Alzheimer’s Drugs Falls Far Below Expectations
Medicare spending on recently approved Alzheimer’s medications, specifically Leqembi and Kisunla, is significantly lower than federal officials initially anticipated. A spokesperson for the Centers for Medicare and Medicaid Services revealed that uptake has been so muted that the agency does not forecast significant expenditures on these treatments in 2026 or 2027. This represents a dramatic reversal from projections made two years ago, which estimated billions in annual spending for Leqembi alone. Healthcare experts and neurologists attribute this slow adoption to several critical challenges. The drugs require complex administration via intravenous infusion and frequent imaging monitoring, creating logistical burdens. Furthermore, the pool of eligible patients remains limited. Clinical concerns also persist, as the medications offer uncertain meaningful benefits while carrying risks of severe side effects, including brain bleeding. Consequently, the combination of administrative complexity, limited efficacy, and safety concerns has stifled demand, leading to a substantial downward revision in government healthcare spending forecasts for these novel therapies.
Wire timeline
Medicare Spending on New Alzheimer’s Drugs Falls Far Below Expectations
Medicare spending on recently approved Alzheimer’s medications, specifically Leqembi and Kisunla, is significantly lower than federal officials initially anticipated. A spokesperson for the Centers for Medicare and Medicaid Services revealed that uptake has been so muted that the agency does not forecast significant expenditures on these treatments in 2026 or 2027. This represents a dramatic reversal from projections made two years ago, which estimated billions in annual spending for Leqembi alone. Healthcare experts and neurologists attribute this slow adoption to several critical challenges. The drugs require complex administration via intravenous infusion and frequent imaging monitoring, creating logistical burdens. Furthermore, the pool of eligible patients remains limited. Clinical concerns also persist, as the medications offer uncertain meaningful benefits while carrying risks of severe side effects, including brain bleeding. Consequently, the combination of administrative complexity, limited efficacy, and safety concerns has stifled demand, leading to a substantial downward revision in government healthcare spending forecasts for these novel therapies.
STAT